Description

• Daiichi Sankyo, Inc. headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo, Co., Ltd. and a member of the Daiichi Sankyo Group. Global clinical development and regulatory activities are headquartered at Daiichi Sankyo Pharma Development in Edison, New Jersey. Our team of more than 1,400 U.S. employees is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs. We currently market therapies in hypertension, thrombotic disorders, stroke risk reduction, dyslipidemia, diabetes, acute coronary syndrome, opioid-induced constipation and metastatic melanoma. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Groups 2025 Vision to become a Global Pharma Innovator with a Competitive Advantage in Oncology, Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.IMPORTANT NOTE: We are very pleased to announce the location of Daiichi Sankyo, Inc.s new US headquarters where our Parsippany- and Edison-based teams will be co-located in a combined site in early to mid-2017. Our new headquarters will be in Basking Ridge, New Jersey at 211 Mt. Airy Road.
• 

  Headquarters:211 Mt Airy Road , Basking Ridge, New Jersey, United States

  More
• 

  Phone Number: +1 973-359-2600

• 

  Website: https://www.dsi.com

• 

  Employees:3223

• 

  Revenue:$500M - 1B

• 

  Legal Name:Daiichi Sankyo, Inc.

• Daiichi Sankyo, Inc.'s Social Media

  
• Is this data correct?

• |  NAICS Code: 446110  |

  Show More